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Abstract
Background—Cardiac transplantation is an excellent treatment for end-stage heart disease. 
However, rejection of the donor graft, particularly by chronic rejection leading to cardiac allograft 
vasculopathy, remains a major cause of graft loss. The lymphatic system plays a crucial role in the 
alloimmune response, facilitating trafficking of antigen presenting cells (APCs) to draining lymph 
nodes (dLN). The encounter of APCs with T lymphocytes in secondary lymphoid organs is 
essential for the initiation of alloimmunity. Donor lymphatic vessels are not anastomosed to that of 
the recipient during transplantation. The pathophysiology of lymphatic disruption is unknown and 
whether this disruption enhances or hinders the alloimmune responses is unclear. Although 
histological analysis of lymphatic vessels in donor grafts can yield information on the structure of 
the lymphatics, the function, however, following cardiac transplantation is poorly understood.
Methods—Using Single photon emission computed tomography/CT (SPECT/CT) 
lymphoscintigraphy, we quantified the lymphatic flow index (LFI) following heterotrophic cardiac 
transplantation in a murine model of chronic rejection.
Results—Ten weeks following transplantation of a minor antigen (HY) gender-mismatched heart 
graft, the LFI was significantly increased compared with gender-matched controls. Furthermore, 
the enhanced LFI correlated with an increase in donor cells in the mediastinal dLN; increased 
lymphatic vessel area; and graft infiltration of CD4+, CD8+ T-cells and CD68+ macrophages.
Conclusions—Chronic rejection results in increased lymphatic flow from the donor graft to 
dLNs, which may be a factor in promoting cellular trafficking, alloimmunity, and cardiac allograft 
vasculopathy.
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Introduction
Heart transplantation is currently the best treatment for patients with end-stage heart failure. 
With the development of more potent immunosuppression, the one-year survival rate has 
risen to 85% in the UK1. However, immunosuppressive drugs have several metabolic, 
infectious, renal and neoplastic side effects2 and have not prevented the development of 
cardiac allograft vasculopathy (CAV); the main limitation of long-term survival of heart 
transplant recipients3–5. Histologically, CAV presents as a complex interplay between 
proliferative myoblasts, macrophages and T-lymphocytes leading to the formation of a neo-
intima5. There is a need to understand the factors that are responsible for CAV in order to 
develop targeted treatment to prevent it.
Following heart transplantation, the cytokine milieu that results due to ischemia/reperfusion 
injury activates donor passenger leukocytes (DPL) to migrate out of the graft6. DPL can 
traffic in the blood circulation to the spleen via reverse transmigration where they can elicit 
an immune response7. Alternatively, they can traffic to draining lymph nodes (dLN) via 
lymphatic vessels. During transplantation, donor lymphatic vessels are not reconnected to 
that of the recipient, this period coincides with the priming of the alloimmune response8. It 
is hypothesised that the accelerated coronary atherosclerosis seen in heart transplant 
recipients is a result of this interrupted lymphatic drainage after surgery9. Our laboratory has 
demonstrated that DPL exit the donor graft via the severed ends of donor lymphatics vessels 
are taken up by recipient lymphatic capillaries and traffic to recipient dLN where they elicit 
a donor-specific T-cell-driven immune response8.
In our model of mouse heterotopic cardiac transplantation, reconnection of donor lymphatic 
vessels to those of the recipient occurred by four weeks8. In the context of inflammation, 
remodelling of lymphatics within the donor organ post-transplantation occurs by 
lymphangiogenesis and can be divided into (i) re-connection of donor lymphatics to that of 
the recipient, and (ii) de novo neogenesis10–12, due to infiltration of macrophages 
expressing LYVE-1, Prox-1, VEGFR-3, and VEGF-C12. Both mechanisms are likely to 
influence the lymphatic flow rate from the donor graft, which may influence the subsequent 
immune response. Studies of lymphangiogenesis have mainly focused on renal and corneal, 
rather than cardiac allograft models10, 11 or have not investigated lymphatic flow4, 13. 
Therefore, translation of the processes of lymphangiogenesis into a model of heterotrophic 
cardiac transplantation, in addition to the investigation of lymphatic flow, in this study is 
novel.
Although the density and size of lymphatic vessels in transplanted hearts have been shown to 
increase in preclinical models4, 13; its implication is not clear for clinical cardiac transplant 
samples, where increased lymphatic density has been linked to both rejection14, 15 and 
tolerance16. Crucially, whether lymphangiogenesis and increased lymphatic vessel density 
observed following cardiac transplantation does lead to increased lymphatic flow and 
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cellular trafficking is unknown, due to the lack of objective quantitative measurement of 
lymph flow after transplantation. While increased lymphatic vessel density could enhance 
DPL trafficking, antigen presentation, and alloimmunity; decreased lymphatic vessel density 
could lead to oedema, which accompanies acute organ rejection in many cases17. Whether 
changes in lymphatic density detected on histological studies are cause or effect of the 
immune process is unknown. Furthermore, the effects of transplant rejection itself on the 
structure, and more importantly, the function of lymphatic vessels remains unclear. 
Therefore, whether lymphangiogenesis is beneficial or detrimental to graft survival is not 
clear.
Here, we used SPECT/CT lymphoscintigraphy to provide objective quantification of 
lymphatic flow in a pre-clinical model of chronic heart transplant rejection and correlated it 
with graft damage and inflammatory infiltrates to investigate the link between functional 
lymphatic flow and the alloimmune process.
Methods
Animals
C57BL/6 (H-2b) mice were purchased from Harlan UK Ltd. (Oxon, UK). C57BL/6 (H-2b) 
mice expressing the enhanced yellow fluorescent protein targeted to the ROSA-26 locus 
(ROSA-EYFP)18, 19 in which EYFP is expressed ubiquitously, were bred in house. 
Animals were kept in specific pathogen-free animal facilities and used in accordance with 
the Animals (Scientific Procedures) Act 1986.
Cardiac transplantation
Heterotopic cardiac allografts into the abdomen were performed as previously described20, 
21 and grafts were monitored by palpation22 (see supplementary methods).
Single Photon Emission Computed Tomography/CT (SPECT/CT) lymphoscintigraphy
At one, five or ten weeks after transplantation, under general anaesthesia, the donor hearts 
were exposed. Nanocoll (GE Healthcare, Buckinghamshire, UK), consisting of 30MBq of 
Technetium-99m (Tc-99m) labelled human albumin nanoparticle in 0.1 mL saline, was 
injected directly into the left ventricular wall at the apex. Injection of nanocoll is a validated 
approach to detect lymphatic flow in humans. The incision was then closed and the animals 
positioned in a nanoSPECT/CT preclinical imager (Bioscan Inc. Washington, DC, USA) 
imaged as described previously8. SPECT/CT images are taken after injection of nanocoll 
into the apex of transplanted hearts. After the final scan, the mice were sacrificed and the 
donor heart graft and the recipient’s dLN were harvested. Using the Invivoscope software 
(Bioscan, Inc.) a sphere is drawn around each “region of interest” for quantification of the 
level of radioactivity within the sphere (Figure 1j; blue & red sphere). The concentration of 
radiation determined (Invivoscope software) to be present (MBq) at both scan times is decay 
corrected to the initial time of the injection of the Nanocoll. The decay corrected values are 
used to quantify the lymphatic flow index (Figure 1k). Heterotopic transplantation of donor 
hearts in this model results in donor lymph draining into the mediastinal (m)dLN of the 
recipients. Scanning of heart recipients at multiple time points after injection of Nanocoll 
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allows quantification of the rate of accumulation of radioactivity in the mdLN as a 
percentage of the injected dose into the myocardium, providing an objective measurement of 
lymphatic function, the lymphatic flow index (LFI) (Figure 1j-l). Although this does not give 
an absolute measurement of lymphatic flow, it provides an objective quantitative assessment 
of the lymphatic function of the transplanted organ.
Evan's Blue dye injection
Ten μL of 0.5%w/v Evans Blue (Sigma-Aldridge, Dorset UK) dye was injected into the left 
ventricular wall of the donor hearts at the apex. Twenty minutes later, the recipient mouse 
was dissected to directly visualise the pattern of lymph drainage so that the dLN could be 
identified.
Immunohistochemistry
Donor grafts were harvested and processed for immunohistochemistry; sections were stained 
with antibodies against CD4 (BD Pharmingen, Oxford, UK), CD8 (BD Pharmingen), CD68 
(Serotec, Oxford, UK), or LYVE1 (Abcam plc, Cambridge, UK), as previously described23 
(see supplementary methods). To determine the cross-sectional area of the lymphatic 
vessels. Images of MPF were analysed with Image J software. To determine if vessels were 
of donor or recipient in origin, staining of lymphatic vessels was performed using a modified 
protocol. The recipient EYFP cell signal was amplified with FITC conjugated goat anti-YFP 
(Abcam plc) as described in the supplementary methods.
Histology
Donor heart graft tissue was harvested and graft vasculopathy was confirmed by Elastic Van 
Gieson staining (Sigma-Aldridge), which was carried out per manufacturer's instructions as 
described previously5 (see supplementary methods).
Quantitative PCR
Genomic DNA from dLNs was isolated using a DNeasy Blood & Tissue extraction kit per 
the manufacture’s instructions (Qiagen, Manchester, UK). DNA concentration was 
quantified with a Nanodrop ND-1000 spectra-photometer. The Y-chromosome specific gene, 
Zfy1, was amplified using quantitative Real-time PCR. The presence of male donor-derived 
cells in the female recipient dLN was calculated against a standard curve of a known 
percentage of male DNAs as previously reported 24, 25 (See supplementary methods).
Statistics
Normality of distributions was calculated using the D'Agostino & Pearson and the Shapiro-
Wilk normality tests to determine further statistical analysis. For figure one, the Mann-
Whitney U test was used to test for significance between the LFI and loss of radiation from 
the graft between HY mismatched and gender-matched transplant recipients. For figures, 
two to four, the Student T-test was used to test for statistical differences between lymphatic 
vessel size and area and infiltrating inflammatory cell scores from different experimental 
groups. The statistical differences between time points for these data sets were analysed by a 
two-way Anova. Allograft immunohistochemical and genomic data was correlated to LFI 
Edwards et al. Page 4
Circulation. Author manuscript; available in PMC 2019 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
using regression analyses (linear, R2) and the Spearman rank correlation coefficient (rs), 
using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). Groups ranged from 
n=4 to 7.
Results
Increased Lymphatic flow index in minor antigen mismatched heart grafts undergoing 
chronic rejection
Although structural changes of lymphatic vessels in donor grafts have been documented, 
objective measurement of the lymphatic function is lacking. We, therefore, used SPECT/CT 
lymphoscintigraphy developed in our laboratory8 and extended it to give quantitative data on 
lymphatic flow after transplantation. SPECT/CT lymphoscintigraphy was performed on 
female EYFP C57BL/6 recipient mice that have received either wild type male or gender-
matched C57BL/6 donor hearts (Figure 1). Gender-mismatched male grafts express the male 
antigen HY, a minor histocompatibility antigen recognised by the female recipient. This 
antigen evokes a chronic rejection response26, resulting in CAV.
Recipients underwent injection of Nanocoll directly into the donor myocardium at the apex 
and SPECT/CT lymphoscintigraphy. At week one, re-connection of donor lymphatic vessels 
to that of the recipient will not have occurred. Scanning was also conducted at week five as 
we have previously shown reconnection of the donor lymphatic vessels occurred by four 
weeks8. Week ten was also chosen to study the effect of de novo neogenesis, within the 
donor graft, on lymphatic flow. Significant CAV would have developed by this time as well.
In this model, lymph flow from the donor organ drains into the mediastinal (m)dLN; which 
was observed at four hours, at week one, in the gender-matched grafts (Figure 1a) and HY-
mismatch grafts (Figure 1b); in the HY-mismatch grafts at week five (Figure 1d, 
supplementary video 1) and ten weeks (Figure 1f). However, in the gender-matched grafts, 
no radioactivity was observed in the mdLN at week five (Figure 1c, supplementary video 2) 
or at ten weeks (Figure 1e).
To provide direct visual evidence of increased lymph drainage ten weeks after 
transplantation in HY-mismatched donor grafts compared with gender-matched grafts, 
Evan's blue, a dye used to track lymph flow was injected into the donor hearts at the apex 
instead of Nanocoll. Figure 1g-i shows that indeed the blue dye can be seen in mdLN above 
the native heart (white arrow) of recipients of HY-mismatched grafts (Figure 1g-h & 
Supplementary Figure 1, yellow arrows), but not in that of recipients of gender-matched 
grafts (Figure 1i).
Scanning of heart recipients at multiple time points after Nanocoll injection allows 
calculation of the rate of radioactivity accumulation into the mdLN (Figure 1j-k) and 
therefore the LFI (Figure 1l); in addition to quantifying the loss of radiation from the 
injected graft (Figure 1m). Figure 1l shows that the LFI is higher at one week following 
transplantation in both graph types, presumably due to enhanced lymphatic leakage via the 
severed donor lymphatics. The LFI was higher in the gender-matched grafts compared with 
the HY-mismatched grafts at 35.093 vs. 10.361 x10-3 % hour-1 respectively (p=0.0080; 
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Figure 1l). The situation is reversed at weeks five and ten (Figure 1l); where lymph flow 
from gender-matched grafts had virtually ceased. The LFI at week five was below the limit 
of detection 0 vs. 22.329 x10-3 % hour-1, for the gender-matched vs. the HY-mismatched 
grafts respectively (p=0.0286), and at week ten, 0 vs. 0.88867 x10-3 % hour-1, respectively 
(p=0.0156).
To confirm that the observed changes, especially the virtual cease of lymph flow from 
gender-matched grafts at weeks five and ten, were not due to lymph flowing to other lymph 
nodes not highlighted in the scan, we quantified the loss of radioactivity from the graft 
(Figure 1m). Indeed, at ten weeks after transplant, four hours after injection of nanocoll, 
while only 72.1 ± 12.02% of injected radioactivity remains within the graft of HY-
mismatched recipients, virtually all (98.7 ± 0.64%) of injected radioactivity has remained 
within the gender-matched grafts (p = 0.0286), confirming that the rate of lymphatic flow 
from gender-matched grafts was indeed very low compared with gender-mismatched grafts.
Chronic rejection is associated with myocardial lymphangiogenesis
To determine if changes in LFI were associated with structural changes of lymphatic vessels 
such as vessel density within donor grafts, vessels were stained with the lymphatic 
endothelial cell marker LYVE-1 (Figure 2a-c). The number of Myocardial lymphatic vessels 
increased five-fold with time in the HY-mismatched grafts (Figure 2d; with a mean of 11.75 
vs. 55 vessels per ten MPF at week one and ten post-transplant, respectively, p=0.038). 
Subepicardium lymphatic density also increased three-fold in HY-mismatched grafts (Figure 
2d; mean of 6.25 vs. 18 per ten MPF), suggesting active lymphangiogenesis has occurred 
during chronic allograft inflammation.
The LYVE-1+ Myocardial lymphatic vessel mean area showed an increase at week five 
compared with week one (Figure 2e) in the HY-mismatched grafts (Mean 252.944μm2 vs. 
647.981μm2, week one and week five, respectively, p=0.0046); which was significantly 
enhanced in comparison to the gender-matched grafts p<0.0001. However, by week ten the 
average vessel area is reduced back to levels similar to week one. The subepicardial 
lymphatic vessel area increased at week ten compared with week one (Figure 2f, mean 
207.354μm2 vs. 469.297μm2, week one and week ten, respectively, p=0.0255); which was 
significantly enhanced in comparison to the gender-matched grafts p=0.0091.
Lymphatic flow index correlates with lymphatic vessel area, but not density
The higher density of lymphatic vessels within donor grafts has been reported previously, 
however, this does not necessarily mean higher lymphatic flow or indeed more efficient 
transport of DPL to dLN. We, therefore, correlated the LFI with the lymphatic vessel 
density. At week one the enhanced LFI observed in the gender-matched grafts correlated 
with the myocardial vessel density (Figure 2g, p=0.0021). No correlation was observed 
between the LFI and lymphatic vessel number in either graft type at the later time points 
(Table 1). However, as not all vessels have the same diameter, we, therefore, correlated LFI 
with the mean lymphatic vessel area. Overall, at all time points, the LFI correlated stongly 
with lymphatic vessel area (Figure 2h-k), except for the subepicardium area in the HY-
mismatch at week five (Figure 2j). At week one, in both graft types, enhanced myocardial 
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lymphatic vessel area correlated with the LFI (Figure 2h, HY-mismatch p=0.0008 & Gender-
matched p=0.0003); this was also the case for the subepicardial vessel area in the gender-
matched grafts (Figure 2i, p=0.008). However, in the HY-mismatched grafts, the reduced 
LFI inversely correlated with enhanced subepicardial vessel area (Figure 2i, p<0.0001). The 
enhanced LFI and myocardial vessel area both observed in the HY-mismatch grafts at week 
five, resulted in the most statistically significant correlation (Figure 2j, p<0.0001, 
R2=0.9861, rs=1), which was not observed in the gender-matched grafts. No correlation was 
observed for the subepicardium area in the HY-mismatch at week five (Figure 2j). At ten 
weeks’ post-transplant in recipients of an HY-mismatch cardiac graft, the LFI did positively 
correlate with an increase in the mean myocardial and subepicardial lymphatic vessel area 
(Figure 2k, HY-mismatch p=0.0222 & Gender-matched p=0.0222). Suggesting that at the 
later time points it is increased area, not the number of vessels that allows an increased flow 
out of the graft.
Donor cells are the main source of neo-lymphangiogenesis in cardiac allografts
In fully MHC-mismatched transplantation models, lymphatic vessels are a combination of 
donor and recipient-derived11. To determine if changes in LFI was due to 
lymphangiogenesis of donor or recipient lymphatic vessels, donor hearts were stained for 
expression of EYFP, expressed only by the recipient. Co-localization of EYFP and LYVE-1 
in sections obtained ten weeks after surgery demonstrated that the vast majority of lymphatic 
vessels were donor derived (Figure 2l-s YFP-/LYVE-1+), with only occasional recipient-
derived (YFP+/LYVE-1+) lymphatic vessels (Figure 2t-w). On quantification, the average 
recipient de novo lymphatic vessel area was 144.72+17.7μm2. This is smaller in comparison 
to the average myocardial vessel area observed at week one of 252.944μm2 and the 
subepicardial lymphatic vessel area of 207.354μm2, however, this is consistent with newly 
forming vessels.
Lymphatic flow index correlates with trafficking of donor cells to draining lymph nodes
Migration of DPL out of donor organs to dLN is a key early event in the initiation of the 
immune response. To determine the number of donor cells that have migrated out of the 
grafts we isolated genomic DNA from the mediastinal dLN to quantify the number of male 
donor cells present after transplantation using a standard curve generated by real-time PCR 
(Figure 3a). One-week post-transplant, 1708 ± 1324 male donor cells (Figure 3b, p = 
0.0019); being 0.12 ± 0.07% of the recipient cells (Figure 3c p = 0.0019) were detected in 
the mdLN following transplantation. The percentage of male donor cells present in dLN of 
recipients strongly correlated with LFI (Figure 3d & Table 2; p<0.0001, rs= 1); as well as the 
number of CD8+ cells within the donor graft in the same recipients (Figure 3e & Table 2; 
p=0.0081, rs = 1), suggesting that higher lymphatic flow rate does facilitate trafficking of 
DPL and the subsequent immune response.
Cardiac Allograft Vasculopathy correlates with increased lymphatic vessel area and 
infiltrating CD8+ T-cells
As the LFI correlates with trafficking of donor cells to dLN, and we have demonstrated 
previously DPL elicit a donor-specific CD8+ T-cell response in the mdLN8; we 
hypothesized that initial variation in LFI from donor grafts to the mdLN could alter the 
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subsequent priming of the immune response and thus cellular infiltration into the graft and 
this, in turn, would lead to graft vasculopahty. Over the time course, the number of CD4+ 
(Figure 4a & 4d), CD8+ (Figure 4b & 4e) and CD68+ (Figure 4c & 4f) cells increased in the 
grafts of HY-mismatched recipients. At the earlier time points, small numbers of CD4+, 
CD8+, and CD68+ cells were seen in the gender-matched grafts however, inflammation had 
resolved after five weeks (Figure 4). In the HY-mismatched graft at week five CD68+ 
macrophages were the predominant infiltrating cell population (Figure 4g), which mirrors 
the HY-mismatched LFI (Figure 1l) and myocardial vessel area (Figure 2e & Figure 2j). The 
percentage of CD8+ cells increased over time in the HY-mismatched graft (Figure 4g) and 
was consistently higher than the gender-matched graft (Figure 4h). Cellular infiltration was 
reflected in graft damage as evident by the development of CAV, determined by vessel 
luminal occlusion (Figure 4i-k), which increased in the transplanted graft over time (Figure 
4l, p<0.0001). There was a strong correlation between CAV, and the number of CD8+ T-cells 
within the HY-mismatched grafts (Figure 4m, Table 3; p<0.0001, rs=1) as well as the mean 
lymphatic vessel area (Figure 4n, p<0.0001,Table 3; rs=1).
The lymphatic flow index and increased lymphatic vessel area correlate with inflammatory 
infiltrate in cardiac grafts
Differences in lymphatic flow from donor grafts are likely to have an influence on the 
inflammatory response. Likewise, the severity of the inflammatory response may also affect 
lymphangiogenesis and lymphatic flow. We, therefore, correlated LFI and lymphatic vessel 
area with inflammatory infiltrates within the donor grafts. Results are summarised in Table 
4. Overall, with HY-mismatch grafts, enhanced LFI and increased lymphatic area, 
respectively, correlated with enhanced CD8+ T-cell infiltration at week one (Figure 4o, 
p=0.0008 & Figure 4p, p<0.0001); and at week 10 (Figure 4q, p=0.0218 & Figure 4r, 
myocardium p=0.0060, subepicardium p=0.0004). Enhanced CD4+ T-cell infiltration also 
correlated with increased lymphatic area in HY-mismatched grafts, in the subepicardium at 
week one (Figure 4s, p<0.0001) and myocardium at week ten (Figure 4t, p=0.0206). 
Interestingly, there is an inverse correlation with CD4+ T-cells (Figure 4s) and CD68+ 
macrophages (Figure 4u, p=0.0016, rs=0.8) and the myocardial vessel area at week one and 
the number of CD68+ macrophages at week ten (Figure 4v, myocardium p<0.0001, 
subepicardium p=0.0008). This may be due to the early processes of lymphangiogenesis; 
where macrophages transdifferentiate into lymphatic endothelial cells11 and CD4+ T-cells 
increase lymphagiogenesis via VEGF-A and VEGF-C expression27. Collectively, indicative 
that the chronic inflammatory environment, in combination with the increased lymphatic 
vessel area, has allowed increased trafficking to the mdLN, and in turn inflammatory cell 
recruitment to the graft.
Discussion
Development of cardiac allograft vasculopathy (CAV), is the main limitation of long-term 
survival of heart transplant patients4. It is hypothesised that CAV is a result of interrupted 
lymphatic drainage after surgery9. We used SPECT/CT lymphoscintigraphy to provide an 
objective quantification of lymphatic flow following transplantation and correlated it with 
the immune response. It is important to note that the parameters measured result in an index, 
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not an actual quantification of lymphatic flow rate in terms of volume per unit time. 
Nonetheless, it provides an objective quantification of lymph flow and allows us to compare 
flow rates between allografts and correlate this with lymphatic density within the donor graft 
and other immunological events. We have chosen a single minor antigen (HY) mismatched 
model to allow time for chronic rejection to develop and any changes in lymphatic vessels 
within the donor graft to take place26. Minor antigens are only recognised by the recipient 
via the indirect pathway of antigen presentation, a route associated with chronic rejection28.
After organ transplantation, donor lymphatics re-connect to the local lymphatic network of 
the recipient. It is now well established that on transplantation of organs into the abdomen, 
the donor organ lymphatics connect to the sub-diaphragmatic network of the recipient, 
which drains to the mediastinal-LN8, 29–32, rather than lymphatic chains more locally, such 
as the mesenteric chain. The reason for this is unclear. To support this observation, we have 
previously demonstrated the presence of high numbers of donor-specific T-cells in the 
mediastinal-LN, but not in irrelevant non-draining LN. Occasionally, mesenteric-LN contain 
a small population of donor-specific T-cells, but it is not a constant feature8. For orthotropic 
heart transplant, as in the clinical situation, donor lymphatics will drain to the local-dLN. 
Although the exact sites may not be well established, the immunological effect should not be 
the same wherever the donor lymph drains, as the dLNs merely provide a niche for the donor 
antigens to meet their cognate alloreactive T-cells, which after activation, traffic via blood to 
the donor graft, resulting in rejection.
The key question we set out to address is whether the higher density of lymphatic vessels 
observed within donor organs after transplantation is associated with enhanced lymphatic 
flow or more efficient transport of DPL to the dLN; leading to enhanced alloimmunity; i.e. 
do changes in lymphatic structure result in changes in function?
In our model, there was an increase in lymphatic density, in concordance with other models 
of cardiac4 and kidney33, 34 mouse and rat transplantation (Figure 2). However, others have 
shown in human and rat cardiac allografts, a lower density of lymphatics correlated with 
rejection13, 16, 35. This may be due to differences in timing or location within the graft, for 
example, in a rat allograft model13 in agreement with our data, a significant increase in 
vessel density is observed within the inner lymphatics, however, a decrease is observed in 
the outer lymphatics. Indeed, variations between different models may indicate that 
determining vessel density by histology alone may not be a reliable indicator of graft 
rejection.
We found a higher LFI in the gender-matched group compared with the HY-mismatched 
group at week one (Figure 1); which correlated with enhanced lymphatic vessel number 
(Figure 2g), as well as, myocardial and subepicardial area (Figure 2h-k). The reason for this 
is unclear, but lymphatic flow out of the graft in the gender-matched recipients may lead to 
beneficial effects such as resolving tissue oedema and promoting clearance of inflammatory 
cells and cytokines to resolve local inflammation32, 36, which does not occur in the HY-
mismatch recipients37. At week one enhanced LFI inversely correlated with reduced 
subepicardial lymphatic vessel area in the HY-mismatched graft (Figure 2i). An oedema, 
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with enhanced cell and fluid load may well be present due to inflammation in the HY-graft, 
which results in increased contractile pressure and lymph flow through the smaller vessels.
The increase in LFI in the HY-mismatched donor grafts compared with gender-matched 
grafts at weeks five and ten (Figure 1) is not surprising, given the number of lymphatic 
vessels is increased; potentially allowing more flow of lymph out of the grafts. However, the 
difference between the HY-mismatched and gender-matched grafts was surprising and is 
disproportionate to the difference in lymphatic vessel density observed between the two 
groups, suggesting that additional factors, such as the inflammatory milieu within HY-
mismatched grafts, may play a role in increasing the lymphatic flow. Furthermore, the LFI 
correlated with lymphatic vessel area, not density (Figure 2 & Table 1). The low LFI to the 
mdLN in gender-matched recipients was not due to drainage to a different set of dLN and 
therefore, was missed by the SPECT/CT scans as evident from the SPECT/CT scans; 
showing a slow rate of nanocoll leaving the grafts, especially at week ten (Figure1m).
In the HY-mismatch recipients, the myocardial lymphatic vessel area peaked at week five 
and decreased subsequently (Figure 2e), the percentage of infiltrating CD68+ macrophages 
corresponded with this (Figure 4g), which also mirrored a peak at weak five in the LFI 
(Figure 1l & Figure 2j). Indicative that the macrophages may play a role in increasing the 
vessel area by trans-differentiation and de novo lymphangiogenesis11. Lymphatic density 
increased with time (Figure 2d), however, despite an increase in density at week ten the LFI 
decreased. In a model of cutaneous hypersensitivity, inflammatory driven lymphatic 
endothelial cell proliferation and lymphatic remodelling did not affect the lymphatic vessel 
density, but vessels increased in size affecting lymph flow38. In addition, to physical factors 
such as vessel area, lymph flow is regulated by complex interactions of phasic, and 
sustained, tonic contractions of the lymphatic smooth muscles; where force and frequency of 
lymphatic contraction can be influenced by a variety of signals including cytokines37. 
Therefore, the active inflammation, and enhanced myocardial lymphatic area, observed in 
week five, may result in the enhanced lymphatic flow observed here.
Previously we have shown in both abdominal and cervical transplantation, leakage from the 
open severed ends of the lymphatic vessels drains into mdLN and that intact lymphatic 
vessels are not essential for flow towards these particular dLN8. By week five the lymphatic 
vessels have reconnected and we speculate therefore that there is no longer any leak into the 
peritoneum in the gender-matched recipients. However, in the HY-mismatch recipients, due 
to the process of inflammatory driven lymphangiogenesis, we observe the lymphatic vessels 
enlarge (Figure 2e) presumably becoming leaky allowing lymph to continue to traffic to the 
mdLN.
We found that LFI at the earliest time point (week one) strongly correlated with the 
percentage of male donor-derived cells determined to be present in the mdLN (Figure 3c). 
This in turn correlated with increased numbers of CD8+ T-cells within the donor graft 
(Figure 3e). The number of CD8+ T-cells within the HY-mismatched grafts correlated with 
the level of CAV, determined by vessel occlusion (Figure 4m). Furthermore, CAV correlated 
with the mean lymphatic vessel area (Figure 4n). There is also a positive correlation with the 
increased CD8+ T-cells and LFI at weeks one (Figure 4o) and ten (Figure 4q); and the mean 
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lymphatic vessel area at weeks one (Figure 4p) and ten (Figure 4r). Increased numbers of 
CD4+ T-cells also correlated with the lymphatic vessel area in the subepicardium at week 
one (Figure 4s) and the myocardium at week ten (Figure 4t). Combined, this data supports 
the notion that increased lymphatic flow is associated with increased trafficking of DPL to 
dLN, which leads to an enhanced subsequent alloimmune response; which we have shown 
previously in our model is CD8+ T-cell driven8. In support of this, in a study of human renal 
transplants34 rejection was caused by a lymphocyte-rich inflammatory infiltrate, attracted by 
CCL21 produced by lymphatic endothelial cells. The authors speculated that neo-
lymphangiogenesis contributed to the export of APCs, which in turn induced an alloreactive 
immune response34. Furthermore, Lakkis et al. concluded that the rejection process is 
dependent on a suitable niche for interactions between APCs and recipient T-cells, with 
rejection being considerably delayed in mice lacking lymph nodes, and completely halted in 
alymphoplastic splenectomised recipients39.
The lymphatic vessel area may be enhanced by the previously reported process of B cell-
driven lymphangiogenesis40. In our model of CAV, we found evidence that the early process 
of lymphangiogenesis appears to be due to the numbers of CD4+ T-cells and CD68+ 
macrophages resident in the graft (Table 4 & Figure 4g, s-v). CD4+ T-cells have been 
previously shown to increase lymphatic vessels density through increased expression of 
VEGF-A and VEGF-C27. Furthermore, macrophages have been shown to play a role in de 
novo lymphangiogenesis11.
Our results indicate that most of the lymphatic vessels were of donor rather than recipient 
origin (Figure 2a-i). This is in concordance with some published data4, 11, but not others41. 
These differences may be due to the different models used. Kerjaschki et al. demonstrated 
that de novo lymphangiogenesis involved incorporation of recipient-derived lymphatic 
progenitors, derived from infiltrating macrophages11 in human kidney allografts. Our model 
is a single minor antigen mismatch, which results in only a moderate degree of 
inflammation, which may not be enough to result in a high proportion of recipient-derived 
lymphatic vessels.
We attempted to correlate LFI with the anti-donor response, such as graft infiltration at later 
time points. Overall, positive correlations were found (Tables 1–4 & Figure 4). However, 
this data must be interpreted with care as LFI and the donor response are clearly 
interdependent, with each having the potential to enhance the other. Therefore, data 
presented here do not provide evidence for cause and effect, but nonetheless, provide some 
insight into the complex interplay between lymphatic function and the inflammatory 
response.
In conclusion, the LFI provides a functional assessment of lymphatic flow following 
transplant. Lymph flow is enhanced in HY-mismatched grafts compared with gender 
matched grafts to a degree that cannot be accounted for by the increased lymphatic vessel 
density alone, implying that inflammation may enhance the flow of lymph. As ischaemia/
reperfusion injury affects lymphatic flow from the heart, and this change is seen before 
myocardial necrosis is visible. Changes in lymphatic drainage could be an early marker of 
heart disease and allow for an early diagnosis42, 43. Therefore, SPECT-CT imaging could 
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prove to be an extremely useful tool in transplantation research and in clinical investigation 
with the potential to be adapted to detect early heart disease. Despite advances in graft 
survival rate, there is still a need for targeted suppression of alloimmunity and subsequent 
eradication of CAV and rejection. The data suggests that interference of lymphatic flow to 
the mdLN at the time of transplant would promote graft survival. Pre-clinical models using 
donors with disrupted lymphatics would definitively prove this point. Treatment with 
inhibitors of lymphatic flow or lymphangiogenesis (e.g. post-harvest using complement 
fixing anti-LYVE-1 antibodies) could be used as a first step to treat patients who have 
received a heart transplant as used in other disease models44, 45 and can be adapted for use 
in transplantation.
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Clinical Perspective
What is new?
• Up to 10–12% of cardiac transplant recipients develop cardiac allograft 
vasculopathy (CAV) each year, making CAV the leading cause of death in 
patients more than 5 years’ post-transplantation.
• It is hypothesised that CAV results due to interrupted lymphatic drainage 
post-surgery.
• Despite this, the lymphatic network of the heart and its role in transplant 
rejection has been largely neglected.
• In this study, we used SPECT/CT lymphoscintigraphy in a pre-clinical model 
providing an objective quantification of lymphatic flow following 
transplantation that could be correlated to CAV; demonstrating that cardiac 
lymphatic remodelling and lymphatic transport dysfunction, post-transplant is 
associated with CAV and transplant rejection.
What are the clinical implications?
• Despite advances in graft survival, there is still a real need for targeted 
eradication of CAV.
• Our findings indicate that lymphatic flow is increased during chronic 
rejection. This, in turn, may result in enhanced trafficking of antigen 
presenting cells to the local draining lymph nodes and an augmented 
alloimmune response.
• Although the cause and effect of this phenomenon are yet to be fully 
established, our data provide the impetus for the investigation of 
lymphangiogenesis inhibition as a means to dampen chronic rejection.
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Figure 1. Quantification of the Lymphatic Flow Index from the cardiac grafts to the mediastinal 
lymph nodes.
SPECT/CT images were taken after injection of nanocoll into the apex of transplanted 
hearts. Representative images are shown (n = 4-5 per group) in four planes the anterior-
posterior view, sagittal, coronal and transverse taken at the same point of the “crosshairs” 
(white). One (a-b), five (c-d) or ten (e-f) weeks after either gender-matched (a, c & e) or HY-
mismatched (b, d & f) abdominal heart transplantation, the animal was scanned 30 min and 
four hours after nanocoll injection. Images are shown at four-hours post-injection. 
Representative examples of direct visualisation of lymph drainage from donor heart grafts 
Edwards et al. Page 16
Circulation. Author manuscript; available in PMC 2019 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
after transplantation using Evan's Blue injection (n=3 in each group). Recipient of HY-
mismatched donor graft showing mdLN, above the native heart (white arrows), staining blue 
with Evan's Blue dye (g & h, yellow arrows). Recipient of gender-matched donor graft 
showing mediastinal not staining blue (i). A sphere is drawn around each “region of interest” 
(j; blue & red sphere) and the radioactivity quantified in the mdLN (j; Yellow arrow; RadLN) 
and the transplanted donor cardiac graft (j; Red arrow; Radgraft). Decay corrected values are 
used to quantify the lymphatic flow index with T1 being the time of the first scan and T2 
being the time of the second scan (k). Shown here is the mean ± SEM, of four to five 
animals at each time point, of the lymphatic flow index (l) or the percentage loss of injected 
radiation from the graft (m); with gender-matched and HY-mismatched grafts at weeks, one, 
five and ten (W1**p = 0.0080, W5*p = 0.0286 & W10*p = 0.0156).
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Figure 2. Quantification of lymphatic density in cardiac donor grafts and determination of the 
origin of LYVE-1+ lymphatic vessels; Lymphatic flow index correlates with lymphatic vessel 
area, but not density.
After SPECT/CT scanning donor grafts were harvested and used for immunofluorescence 
and immunohistochemistry. Images are representative examples of four independent 
experiments; scale bars = 50 μm. Immunohistochemical staining for LYVE-1 was conducted 
in order to quantify the density of subepicardial (a, the black arrows) and myocardial (a, the 
white arrows) lymphatic vessels. Shown is a representative of gender-matched (b) and HY-
mismatched grafts (c) at ten-weeks post-transplant. The black arrows show LYVE-1+ vessels 
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(magnification 200x). LYVE-1+ vessels density (d, *p=0.038) and myocardial (e, ****p 
<0.0001) and subepicardial (f, *p = 0.0091) area (μm2) was determined by two independent 
observers in at least 10 medium power fields, with area determined with Image J software. 
Data are shown as a mean of the two independent observations and four independent 
experiments ± SEM; of gender-matched (GM) and HY-mismatched (HY) grafts at weeks, 
one, five and ten. The lymphatic flow index from each individual mouse was correlated with 
the corresponding LYVE-1+vessel number (g, *p=0.0021) and area at week one (h, 
Myocardium, HY ***p=0.0008, GM ***p=0.0003; i, subepicardium, HY ****p = 0.0008, 
GM ***p=0.0003), week five (j, ****p <0.0001) and week ten (k, *p=0.0222). To determine 
if vessels were of the donor or recipient origin, immunofluorescence was performed with 
anti-LYVE-1 and anti-YFP. Donor lymphatic vessels are EYFP- and LYVE-1+(l-s; white 
arrows). However, the transplant recipients express EYFP and thus recipient lymphatic 
vessels are EYFP+ and LYVE-1+(t-w; yellow arrows). Shown are a representative of 
lymphatic vessel staining in gender-matched grafts (l-o) and HY-mismatched grafts (p-s) 
ten-weeks post-transplant. A representative high power image showing a recipient lymphatic 
vessel within a donor organ is shown (t-w).
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Figure 3. QPCR for donor cells in draining lymph nodes of transplant recipients.
After SPECT/CT imaging, the mdLN were harvested. Genomic DNA was isolated and the 
Y-chromosome specific gene, Zfy1, was amplified using quantitative Real-time PCR. The 
presence of male donor-derived DNA in the female recipient lymph nodes at week one, five 
and ten post-transplant was calculated against a standard curve (a) with a known percentage 
of male DNA, which corresponds to a known number of cells. Allowing for quantification of 
the number of male donor-derived cells (b, **p = 0.0019) as a percentage (c, **p = 0.0019) 
of the total number of cells within the female lymph node. Shown is the mean ±SD of seven 
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mice. The percentage of male cells present in the draining mediastinal lymph nodes at week 
one post-transplant from each individual mouse was correlated with the corresponding 
lymphatic flow index (d, ****p <0.0001) and the number of CD8+ cells (e, *p = 0.0081) 
within the donor graft at week one; the number of CD4+ cells; CD68+ cells; the number of 
vessels and the area of vessels within the donor graft at week one.
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Figure 4. Determination of graft vasculopathy and inflammatory cellular infiltration within the 
transplanted donor grafts.
After SPECT/CT scanning donor grafts were harvested, immunohistochemical staining for 
CD4 (a) CD8 (b), and CD68 (c) were conducted to determine cell numbers (black arrows 
show an example); shown is a representative of HY-mismatched grafts at ten weeks post-
transplant. Images are representative examples of 4 independent experiments; scale bars = 
50 μm. Positive CD4 (d, **p = 0.0079) and CD8 (e, W5GM**p =0.0019, W5HY**p = 
0.0066, W10HY**p = 0.0429, W1GM vs. HY**p = 0.0077, W10GM vs. HY*p = 0.0233) 
cells were counted in 20 random high-power fields (magnification 400x) by two independent 
Edwards et al. Page 22
Circulation. Author manuscript; available in PMC 2019 January 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
observers. For CD68+ macrophage staining (f, W10**p = 0.0079), a 63-point grid was 
overlaid onto a 400x magnification of macrophage staining. The percentages of grid points 
positive for CD68 staining were counted by two independent observers. Data are shown as 
the mean number of cells, per field of view (FoV), of the two independent observations and 
four independent experiments ± SEM; of a gender-matched and HY-mismatched grafts at 
weeks, one, five and ten. Within the infiltrating cells, the percentage of CD68+, CD4+ and 
CD8+ cells was determined in the HY-mismatched (g) and gender-matched grafts (h). 
Immunohistochemical staining for Elastic Van Gieson was performed to determine graft 
vasculopathy. Shown is a representative of a gender-matched (i) and HY-mismatched grafts 
(j & k). Histologically the allograft vasculopathy ranged from median (j) to severe (k) in the 
HY mismatched graft. Characterised by inflammatory cell invasion into the layers of the 
internal to external elastic; shown is the lumen of the vessel (L), the internal elastic (I) and 
the external elastic (E). Measurement of the internal elastic (I) and the external elastic (E) 
can be used to calculate the percentage of luminal occlusion (l, W1*p=0.0121, 
W5*p=0.0357 & W10*p=0.0238; ****p<0.0001). Shown is the percentage luminal 
occlusion in four independent experiments with mean at one, five and ten weeks. The 
percentage luminal occlusion was correlated with CD8+ cell number (m, ****p<0.0001) and 
the mean lymphatic vessel area (n, ****p<0.0001). CD8+ cell number was correlated with 
the LFI (o, W1****p<0.0001 & q, W10*p=0.0218) and the lymphatic vessel area (p, 
myocardial W1****p<0.0001, subepicardial W1***p=0.0008 & r, myocardial 
W10**p=0.006, subepicardial W10***p=0.0004). CD4+ cell number was correlated with 
the lymphatic vessel area (s, myocardial W1*p=0.0287 & subepicardial W1****p<0.0001 & 
t, W10*p=0.0206). CD68+ cell number was correlated with the lymphatic vessel area (u, 
W1**p=0.0016) and density (v, myocardial W10****p<0.0001 & subepicardial 
W10***p=0.0008).
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Table 1
Correlation of the Lymphatic Flow Index (LFI) to the mediastinal dLN with lymphatic 
vessel density within the donor graft.
Time point Week 1 Week 5 Week 10
Graft Type HY Mismatch Gender Matched HY Mismatch Gender Matched HY Mismatch Gender Matched
Correlation
LFI vs. 
Myocardial 
Lymphatic 
Vessel number
p 0.4404 0.0008 *** 0.6789 N/A 0.0325* N/A
R2 0.1021 0.815 0.03056 0.7208
rs 0.6 1 -0.2 -0.5
LFI vs. 
Subepicardial 
Lymphatic 
Vessel number
p 0.3849 0.0476 0.7167 N/A 0.0222* N/A
R2 0.02915 0.01442 0.01442 0.6084
rs -0.4 0.7379 0.2 -1
LFI vs. 
Myocardial 
Lymphatic 
Vessel Area
p 0.0008 *** 0.0003 *** <0.0001 **** N/A 0.0222* N/A
R2 0.8097 0.9053 0.9861 0.8421
rs 1 1 1 1
LFI vs. 
Subepicardial 
Lymphatic 
Vessel Area
p 0.0008 *** 0.0008 *** 0.1418 N/A 0.0222* N/A
R2 0.9334 0.8354 0.3227 0.9794
rs -1 1 0.8 1
R2- using linear regression analyses; rs- Spearman rank correlation coefficient;
p- probability calculated by spearman rank correlation
(* P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001)
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Table 2
Correlation of the percentage of male donor cells in draining lymph nodes (dLN) with 
Lymphatic flow index, inflammatory cell infiltrate or lymphatic vessel density.
Correlation Lymphatic Flow Index Number 
CD4+ cells in 
graft
Number 
CD8+ cells in 
graft
Number 
CD68+ cells 
in graft
Number of 
LYVE-1+ 
lymphatic 
vessels
Area of 
LYVE-1+ 
lymphatic 
vessels
% dLN DNA 
that is male vs.
p <0.0001 **** 0.2264 0.0081* 0.3711 0.3711 0.2005
R2 0.9877 0.3377 0.8566 0.02021 0.2021 0.3632
rs 1 -0.5 1 0.5 0.5 -0.5
R2- using linear regression analyses; rs- Spearman rank correlation coefficient;
p- probability calculated by spearman rank correlation
(* P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001)
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Table 3
Correlation of Chronic Allograft Vasculopathy (CAV) with the number CD8+ cells in 
donor graft or Area of LYVE-1+ lymphatic vessels within the donor graft.
Correlation Number CD8+ cells in graft Area of LYVE-1+ lymphatic vessels
Graft Type HY Mismatch Gender Matched HY Mismatch Gender Matched
Chronic Allograft Vasculopathy (CAV) vs. p <0.0001**** 0.8411 0.0002*** 0.365
R2 0.9999 0.01131 0.9758 0.7052
rs 1 0.5 1 1
R2- using linear regression analyses; rs- Spearman rank correlation coefficient;
p- probability calculated by spearman rank correlation
(* P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001)
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Table 4
Correlation of the Lymphatic Flow Index (LFI) to the mediastinal dLN with 
inflammatory cell infiltrate within the donor graft.
Time point Week 1 Week 5 Week 10
Graft Type HY Mismatch Gender Matched HY Mismatch Gender Matched HY Mismatch Gender Matched
Correlation
LFI vs. 
Number CD4+ 
cells in graft
p 0.0218* 0.0028** 0.2972 N/A 0.2972 N/A
R2 0.8016 0.9987 0.05537 0.7907
rs -0.8 1 -0.5 0.5
LFI vs. 
Number CD8+ 
cells in graft
p <0.0001**** 0.0028** 0.2972 N/A 0.0218* N/A
R2 0.9513 0.9199 0.05537 0.7758
rs 1 1 -0.5 0.8
LFI vs. 
Number 
CD68+ cells in 
graft
p 0.3268 0.0469* 0.0028** N/A 0.0028** N/A
R2 0.007507 0.6682 0.7409 0.9864
rs -0.4 -1 1 1
Myocardial 
Vessel Area vs. 
Number CD4+ 
cells in graft
p 0.0287* 0.0004*** 0.2012 0.3333 0.0206* 0.7639
R2 0.5774 0.8901 0.3686 1 0.6903 0.3286
rs -0.8 1 0.5 -1 0.6981 -0.434
Subepicardial 
Vessel Area vs. 
Number CD4+ 
cells in graft
p <0.0001**** 0.0016*** 0.7316 0.3333 0.0594 0.4591
R2 0.9354 0.8305 0.03274 1 0.5414 0.1139
rs 1 1 -0.5 1 0.6981 0.06143
Myocardial 
Vessel Area vs. 
Number CD8+ 
cells in graft
p <0.0001**** 0.0180* 0.2012 0.3333 0.0060** 0.0029**
R2 0.9445 0.6345 0.3686 1 0.7423 0.9129
rs 1 1 0.5 -1 0.8 -0.5
Subepicardial 
Vessel Area vs. 
Number CD8+ 
cells in graft
p 0.0008*** 0.0586 0.7316 0.4222 0.0004*** 0.1192
R2 0.8368 0.4752 0.0327 1 0.8923 0.4943
rs 1 1 -0.5 1 0.8 -0.5
Myocardial 
Vessel Area vs. 
Number 
CD68+ cells in 
graft
p 0.0016** 0.1288 0.2250 0.0222* 0.1734 0.0381*
R2 0.8329 0.3406 0.3394 0.8714 0.2845 0.8013
rs -0.4 -0.8 0.5 -1 -0.2 -0.8
Subepicardial 
Vessel Area vs. 
Number 
CD68+ cells in 
graft
p 0.5620 0.0729 0.0222* 0.0222* 0.7064 0.0048**
R2 0.05906 0.4402 0.9869 0.835 0.02536 0.9485
rs 0.4 -0.8 1 1 -0.2 -0.9487
Myocardial 
Vessel number 
vs. Number 
CD68+ cells in 
graft
p 0.1052 0.0365* 0.3486 0.3861 <0.0001**** 0.2677
R2 0.3773 0.5449 0.2195 0.1911 0.9296 0.1992
rs 0.4 -0.8 -0.5 0.5 -0.8 -0.6325
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Time point Week 1 Week 5 Week 10
Graft Type HY Mismatch Gender Matched HY Mismatch Gender Matched HY Mismatch Gender Matched
Subepicardial 
LV number vs. 
Number 
CD68+ cells in 
graft
p 0.2152 0.2156 0.1310 0.4222 0.0169* 0.0493*
R2 0.2424 0.2643 0.4731 0.9919 0.6412 0.5015
rs 0.6 0.6 -0.7379 0.5 -1 -1
R2- using linear regression analyses; rs- Spearman rank correlation coefficient;
p- probability calculated by spearman rank correlation
(* P ≤ 0.05 ** P ≤ 0.01 *** P ≤ 0.001 **** P ≤ 0.0001)
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